Durability of Response and Characterisation of Corneal events with Extended follow-up after Belantamab Mafodotin monotherapy for patients with relapsed/refractory Multiple Myeloma

Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma

“…During this last decade, another major inflection point was the development of several monoclonal antibodies, including the CS1/SLAMF7-targeting elotuzumab (Lonial et al 2015) and the CD38targeting antibodies daratumumab (Lokhorst et al 2015;Dimopoulos et al 2016b;Palumbo et al 2016;Mateos et al 2018;Facon et al 2019) and isatuximab (Martin et al 2017;Mikhael et al 2019Mikhael et al , 2020Dimopoulos et al 2020). In addition, BCMA (TNFRSF17) has already emerged as a major therapeutic target for MM, with promising results in clinical trials for several different classes of therapeutics that target BCMA, including chimeric antigen receptor T (CAR-T) cells (Madduri et al 2019;Raje et al 2019;Yan et al 2019), antibody drug conjugates (ADCs) (Panowski et al 2019;Popat et al 2019Popat et al , 2020Trudel et al 2019a;Lonial et al 2020), or bispecific antibodies as T-cell engagers (Topp et al 2016(Topp et al , 2018Seckinger et al 2017;Dilillo et al 2018;Einsele et al 2019;Li et al 2019;Frerichs et al 2020). In addition, the histone deacetylase inhibitor panobinostat (LBH-589) is U.S. Federal Drug Administration (FDA)-approved (for use in combination with bortezomib) (San- Miguel et al 2013Miguel et al , 2014Manasanch et al 2018), whereas promising clinical results have been reported with the use of venetoclax, especially in MM patients with the t(11;14) translocation (Kaufman et al 2017(Kaufman et al , 2019aKumar et al 2017;Harrison et al 2019).…”

“…In parallel with the clinical successes of daratumumab and other monoclonal antibodies, two additional exciting areas of progress in MM have involved the development of CAR-T cells (e.g., Brudno et al 2018;Cohen et al 2019;Raje et al 2019) and of ADCs (Panowski et al 2019;Popat et al 2019Popat et al , 2020Trudel et al 2019a;Lonial et al 2020). For both of these modalities, the most pronounced progress in MM has been achieved through targeting of the B-cell maturation antigen (BCMA), in view of its nearly universal expression (despite variable intensity) on the surface of MM cells and the relatively restricted expression of this antigen on normal or malignant plasma cells (O'Connor et al 2004).…”